DIESE MELDUNG PER E-MAIL VERSENDEN
MedDay announces its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis meets primary endpoint
*
marks required fields
Name des Empfängers:
*
E-Mail des Empfängers:
Nachricht:
*
Enter security words: